Clinical trial
Voraxaze for Delayed Methotrexate Clearance
NCT00424645 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00424645 |
|---|---|
| Title | Voraxaze for Delayed Methotrexate Clearance |
| Official title | Randomized, Double-Blind, Placebo Controlled Trial of Voraxaze™ in Patients With a Delayed MTX Clearance |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | BTG International Inc. |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hematologic Malignancy, Solid Tumor |
| Intervention type | Drug |
| Interventions | Voraxaze (Glucarpidase), Placebo |
| Enrollment | 3 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Jan 19, 2007 |
| Last update posted | Dec 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: